PHARMACOGENETICS OF ANTIDEPRESSANT RESPONSE AND REMISSION: TOWARD GENOTYPE-GUIDED PRESCRIBING IN MAJOR DEPRESSIVE DISORDER
PHARMACOGENETICS OF ANTIDEPRESSANT RESPONSE AND REMISSION: TOWARD GENOTYPE-GUIDED PRESCRIBING IN MAJOR DEPRESSIVE DISORDER
抗抑郁药反应和缓解的药物遗传学：针对重度抑郁症的基因型指导处方
批准号：
nhmrc : 1127700
负责人：
Dr Chad Bousman
金额：
$29.04万
依托单位国家：
澳大利亚
项目类别：
Career Development Fellowships
财政年份：
2017
资助国家：
澳大利亚
项目状态：
已结题
起止时间：
2017-01-01 至 2020-12-31
中文摘要
翻译
抑郁症的抗抑郁药物治疗“一刀切”的方法并不是最理想的。目前的技术和科学数据支持向抗抑郁药物治疗的个性化方法过渡。我的研究将(1)开发和测试基于遗传的算法来预测抗抑郁药物的反应和缓解的能力，以及(2)评估当前可用的算法在临床实践中的临床有效性和实用性。
英文摘要
A “one-size fits all” approach to antidepressant pharmacotherapy in depression is suboptimal. Current technology and scientific data support the transition to a personalised approach to antidepressant pharmacotherapy. My research will (1) develop and test genetic based algorithms for their ability to predict antidepressant response and remission and (2) evaluate the clinical validity and utility of currently available algorithms in clinical practice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Kava for the Treatment of Generalized Anxiety Disorder: A 16-Week Double-Blind RCT
-
批准号：nhmrc : 1063383
-
项目类别：Project Grants
-
资助金额：$45.38万
-
财政年份：2014
-
负责人：Dr Chad Bousman
-
依托单位：
The Efficacy of Adjunctive S-Adenosyl Methionine (SAMe) versus a Combination Nutraceutical in Clinical Depression: A Double-Blind, Randomised, Placebo-Controlled Trial
-
批准号：nhmrc : 1048222
-
项目类别：Project Grants
-
资助金额：$53.36万
-
财政年份：2013
-
负责人：Dr Chad Bousman
-
依托单位：
海外基金
